Skyline Diagnostics SkylineDx, NeraCare Partnering on Proteomic Test for Melanoma The companies inked a codevelopment and licensing agreement for NeraCare's Immunoprint test for identifying high-risk early-stage melanoma patients. SkylineDx Gains CE-IVD Mark for Melanoma Metastasis Risk Assay The Netherlands-based firm is partnering with Belgian company Biocartis on European commercialization of the qPCR assay, which could reduce unnecessary surgeries. SkylineDx, VIB Form Molecular Diagnostics Partnership The partnership will focus on high-potential in vitro diagnostic opportunities for unmet medical needs for global markets. Biocartis, SkylineDx Partner to Develop Melanoma Nodal Metastasis Risk Test The Belgian molecular diagnostics firm also reported a 70 percent year-over-year increase in commercial cartridge volumes in the first quarter. SkylineDx, Imperial College London, UCSD Partner to Develop Kawasaki Disease Test The test is based on 13 genes that form a gene signature in the blood of children with Kawasaki disease, and it enables KD to be distinguished from other diseases. Mar 24, 2020 SkylineDx, BioInvent Collaborate to Characterize Predictive Immunological Signatures for Cancers Mar 12, 2020 DIAMONDS Project Using New Classification Approach to Develop Rapid Infectious Disease Tests Premium Feb 4, 2020 SkylineDx Partners With German Hospital to Assess Multiple Myeloma Test Sep 24, 2019 SkylineDx Partners With Mayo Clinic on Melanoma Risk Test Study Ahead of Planned US Trial Premium Sep 3, 2019 SkylineDx Secures $21.9M Investment Jun 28, 2019 In Brief This Week: Invitae, Personalis, Seegene, Precipio, SkylineDx, and More Jan 31, 2018 SkylineDx, Mayo Clinic to Develop Diagnostic Tests for Melanoma Dec 20, 2017 Skyline Medical to Acquire Up to 25 Percent of Helomics Apr 18, 2017 SkylineDx Develops Tool to Predict Cancer Therapies Based on Genomic Data Premium Oct 21, 2016 SkylineDx Follows Multiple Myeloma MDx With Collaborative Effort to Develop Therapy Selection Assay Premium Nov 25, 2015 SkylineDx Lands CE-IVD Mark for MMProfiler Apr 1, 2014 SkylineDx Opens US Office to Market Multiple Myeloma Test to American Clinicians, Pharma Premium Sep 24, 2013 Newly Formed SkylineDx Acquires Array Tests, IP, Other Assets of Defunct Skyline Diagnostics Premium Jan 2, 2013 People in the News: Kurt Schmidt, Henk Viëtor Premium Jun 26, 2012 Skyline Dx Partners with LabPMM to Offer Array-based AML Testing Service in Europe Premium Sep 7, 2011 Clavis Pharma Taps Skyline Dx for Array-based Patient Selection in AML Drug Trial Premium Sep 6, 2011 Skyline, Clavis Partner on Biomarkers for AML Drug Jul 26, 2011 Skyline Dx, Janssen Partner on Adverse Reaction Risk Test for Multiple Myeloma Drug Premium Jul 6, 2011 Skyline Dx, Janssen Partner on Companion Dx Deal Mar 22, 2011 New Product Watch: Mar 22, 2011 Premium Load More Breaking News Verily Awarded CDC Contract for Wastewater Surveillance Genomic Health to Pay $32.5M to Resolve Cancer Test False Claims Allegations by DOJ Vela Diagnostics Inks Japan Distribution Agreement for HIV-1 Drug Resistance Tests Coronary Artery Calcification Contributors, Potential Drug Targets Found in Cross-Ancestry GWAS Max Planck Team Uses Spatial Single-Cell Proteomics Method to Analyze Hepatocyte Heterogeneity The Scan Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants. Small Study of Gene Editing to Treat Sickle Cell Disease In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms. Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema. Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.